Products for Research Use Only

Radotinib-d6

CAT: 0804-HY-15728S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15728S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Radotinib-d6 is deuterium labeled Radotinib. Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells. Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases[1][2].
CAS Number
2754051-83-5
Product Name Alternative
IY-5511-d6
UNSPSC
12352005
Target
Apoptosis; Bcr-Abl; Isotope-Labeled Compounds; JAK; Prion Protein; STAT
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Neuronal Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection; Neurological Disease
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=C([2H])C([2H])=C(C([2H])([2H])[2H])C(NC4=NC=CC(C5=NC=CN=C5)=N4)=C3[2H]
Molecular Formula
C27H15D6F3N8O
Molecular Weight
536.54
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kim SH, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99 (7) :1191-6.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported